

Supplementary Table 1. Quality of Included Studies as Assessed by the Newcastle-Ottawa Scale

Study	Selection ^a	Comparability ^a	Outcome ^a	Total Score (out of 9) ^b
mPC Studies				
Beyer 2016 ⁴⁷	****	*	***	8
Park 2016 ³¹	***	**	*	6
Patel 2016 ³⁴	****	**	**	8
Schmidt 2016 ²⁴	****	**	**	8
Abrams 2017 ¹¹	****	**	***	9
Braiteh 2017 ²⁵	****	**	***	9
Caponnetto 2017 ⁴⁸	***	*	**	6
Kim 2017 ³³	****	**	***	9
Mañes-Sevilla 2017 ²⁶	****	*	***	8
McBride 2017 ³⁵	****	*	**	7
Watanabe 2017 ¹⁹	***	*	*	5
Barrera 2018 ³⁰	****	*	***	8
Cartwright 2018 ¹⁶	****	*	***	8
Cho 2018 ²⁹	****	**	**	8
Kang 2018 ¹⁸	****	*	***	8
Kim 2018 ¹⁷	****	**	***	9
Pacheco-Barcia 2018 ⁴⁶				
Vivaldi 2018 ⁴⁹				
Barrera 2019 ³²	***	**	*	6
Henkel 2019 ⁵⁰	***	**	*	6
Javed 2019 ⁵¹	****	*	***	8
aPC Studies				
Cherniawsky 2017 ⁵²	***	**	*	6
Kasi 2017 ²¹	***	*	*	5
Maeda 2017 ⁵³	***	*	**	6
Muranaka 2017 ²⁰	****	*	**	7
Papneja 2017 ²⁷	****	**	***	9
Shahda 2017 ⁵⁴	****	**	*	7
Wang 2017 ²⁸	****	*	***	8
Franco 2018 ⁵⁵	****	*	***	8
Helen 2018 ⁵⁶	****	**	***	9
Kudlovich 2018 ⁵⁷	****	**	**	8
Tahara 2018 ²²	***	*	**	6

Terashima 2018 ²³	****	*	***	8
Hegewisch-Becker 2019 ⁵⁸	****	*	***	8
Mean NOS score				7.47

aPC, advanced pancreatic cancer; mPC, metastatic pancreatic cancer; NOS, Newcastle-Ottawa Scale.

^a The Newcastle-Ottawa Scale assigns a maximum of 4, 2, and 3 stars for selection, comparability, and outcome parameters, respectively.

^b A total score of 9 denotes the highest quality.

